SCHEMBL29636718

SCHEMBL29636718

[2H]c1cc2ccccc2nc1-c1ccc(OC)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.73
NPC1 O15118 6/20 0.73
RAB9A P51151 6/20 0.73
ALDH1A1 P00352 5/20 0.73
SMN1; SMN2 Q16637 4/20 0.73
NFKB1 P19838 1/20 0.73
NFKB2 Q00653 1/20 0.73
RELA Q04206 1/20 0.73
LMNA P02545 2/20 0.54
MAPT P10636 2/20 0.54
ACACA Q13085 1/20 0.54
HPGD P15428 1/20 0.54
HTT P42858 1/20 0.54
ACP1 P24666 6/20 0.52
NPSR1 Q6W5P4 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
PKM P14618 2/20 0.49
AURKA O14965 1/20 0.48
AURKB Q96GD4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29636725 0.85 NPC1 (1.00) KDM4ENPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL707767 0.85 NPC1 (1.00) KDM4ENPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL27610819 0.83 NPC1 (0.97) KDM4ENPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL6858674 0.83 NPC1 (0.97) KDM4ENPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL12393772 0.78 KDM4E (0.85) KDM4ENPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL18774821 0.74 ALDH1A1 (0.72) KDM4ENPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL710433 0.73 NPC1 (0.71) KDM4ENPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL16404354 0.72 CYP1A2 (0.62) KDM4ENPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL29636789 0.72 MAPT (0.71) KDM4ENPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL6534318 0.72 MAPT (0.71) KDM4ENPC1RAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4017492-A1 MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS Biohaven Therapeutics Ltd. (US) 2022-06-29 EP claimed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
EP-4017492-A1 MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS Biohaven Therapeutics Ltd. (US) 2022-06-29 EP disclosed